argenx SE
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
Registration date
04 mar 2015 - 07:28
Statutory name
argenx SE
Title
arGEN-X EXPANDS PRECLINICAL PIPELINE WITH ARGX-115: A NOVEL SIMPLE ANTIBODY(TM) FOR CANCER IMMUNOTHERAPY
Comments
• ARGX-115 re-activates immunity to cancer
• First-in-class therapeutic antibody targeting GARP, a novel immune checkpoint
• First candidate to be licensed under Company's Innovative Access Program
Related downloads
Date last update: 11 April 2026